| abstract |
The present invention relates to general formula (I) wherein R 1 is hydrogen, lower alkyl, — (CH 2 ) n —CF 3 , — (CH 2 ) n —CHF 2 , — (CH 2 ) n —CN , — (CH 2 ) n -cycloalkyl, — (CH 2 ) n —O-lower alkyl, — (CH 2 ) n —O-cycloalkyl or — (CH 2 ) n —C (O) O-lower alkyl R 2 represents hydrogen, lower alkyl, lower alkoxy, halogen, —C (O) -lower alkyl, —C (O) OH, —C (O) O-lower alkyl, —NR 3 R 4 or — C (O) —NR 3 R 4 , wherein R 3 and R 4 may be independently of each other hydrogen or lower alkyl; X is —O—, —S—, —CH 2 —. , -OCH 2 -, or does not form a bridge shows the two hydrogen atoms; and, n is 0, 1 2H-tetrazol-5-yl-amide derivatives, as well as pharmaceutically acceptable salts thereof. The compounds of general formula (I) are group 1 metabotropic glutamate receptor agonists (mGluR) and are therefore useful in the treatment of the corresponding CNS-diseases. |